Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched hematopoietic stem cell transplantation (HSCT) is safe and effective for patients aged 5-45 years with primary immunodeficiency (PID) and end-stage lung disease.

NCT Number	NCT01852370
Lead Sponsor	Paul Szabolcs
Conditions	Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease +1 more
Enrollment	16 participants
Start Date	2013-06-20
Primary Completion	2026-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2025-12-15